Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Nine Months Ended September 30, 2021
October 15, 2021 at 03:16 pm IST
Share
Shanghai Haohai Biological Technology Co., Ltd. provided group earnings guidance for the nine months ended September 30, 2021. The board of directors of the company hereby informs the shareholders of the company and potential investors of the company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the nine months ended 30 September 2021, the Group is expected to record an unaudited net profit attributable to shareholders of the company of approximately RMB 300,000,000 to RMB 330,000,000 during the Reporting Period, representing an increase of approximately RMB 187,353,100 to RMB 217,353,100, or approximately 166.32% to 192.95%, as compared to that in 2020 (corresponding period in 2020: an unaudited net profit attributable to shareholders of the Company of RMB 112,646,895.39). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 280,000,000 to RMB 310,000,000, representing an increase of approximately RMB 187,985,800 to RMB 217,985,800, or approximately 204.30% to 236.90%, as compared to that in 2020 (corresponding period in 2020: unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB 92,014,160.78).
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.